GAPLINC:gastric adenocarcinoma predictive long intergenic noncoding RNA
GAPLINC is a 924-bp-long lncRNA that is highly expressed in gastric cancer tissues
Manipulating GAPLINC expression alters CD44 mRNA abundance and the effects of GAPLINC on cell migration and proliferation are neutralized by suppressing CD44 expression. And GAPLINC regulates CD44 as a molecular decoy for miR211-3p, a microRNA that targets both CD44 and GAPLINC. Tissue ISH analysis suggests that GAPLINC overexpression defines a subgroup of patients with gastric cancer with very poor survival.
The expression levels of GAPLINC is most upregulated in gastric cancer compared with normal tissue based on ISH. In addition, GAPLINC expression correlates with poor outcome of gastric cancers.
>gi|578888097|ref|NR_110429.1| Homo sapiens gastric adenocarcinoma associated, positive CD44 regulator, long intergenic non-coding RNA (GAPLINC), transcript variant 1, long non-coding RNA
Labs working on this lncRNA
- State Key Laboratory for Oncogenes and Related Genes; Division of Gastroenterology and Hepatology, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- Hu Y, Wang J, Qian J, Kong X, Tang J, Wang Y, Chen H, Hong J, Zou W, Chen Y, Xu J, Fang JY. Long noncoding RNA GAPLINC regulates CD44-dependent cell invasiveness and associates with poor prognosis of gastric cancer. Cancer Res. 2014 Dec 1;74(23):6890-902.